Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash & Equivalents: 2013-2025

Historic Cash & Equivalents for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to $344.8 million.

  • Ocular Therapeutix's Cash & Equivalents fell 19.30% to $344.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $344.8 million, marking a year-over-year decrease of 19.30%. This contributed to the annual value of $392.1 million for FY2024, which is 100.25% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Cash & Equivalents of $344.8 million as of Q3 2025, which was down 11.85% from $391.1 million recorded in Q2 2025.
  • Ocular Therapeutix's Cash & Equivalents' 5-year high stood at $482.9 million during Q1 2024, with a 5-year trough of $66.6 million in Q2 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $349.7 million (2025), whereas its average is $300.0 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 50.49% in 2023, then spiked by 590.16% in 2024.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Cash & Equivalents stood at $164.2 million in 2021, then tumbled by 37.68% to $102.3 million in 2022, then spiked by 91.40% to $195.8 million in 2023, then spiked by 100.25% to $392.1 million in 2024, then decreased by 19.30% to $344.8 million in 2025.
  • Its Cash & Equivalents was $344.8 million in Q3 2025, compared to $391.1 million in Q2 2025 and $349.7 million in Q1 2025.